1
|
Biasizzo M, Javoršek U, Vidak E, Zarić M, Turk B. Cysteine cathepsins: A long and winding road towards clinics. Mol Aspects Med 2022; 88:101150. [PMID: 36283280 DOI: 10.1016/j.mam.2022.101150] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Revised: 10/13/2022] [Accepted: 10/14/2022] [Indexed: 12/03/2022]
Abstract
Biomedical research often focuses on properties that differentiate between diseased and healthy tissue; one of the current focuses is elevated expression and altered localisation of proteases. Among these proteases, dysregulation of cysteine cathepsins can frequently be observed in inflammation-associated diseases, which tips the functional balance from normal physiological to pathological manifestations. Their overexpression and secretion regularly exhibit a strong correlation with the development and progression of such diseases, making them attractive pharmacological targets. But beyond their mostly detrimental role in inflammation-associated diseases, cysteine cathepsins are physiologically highly important enzymes involved in various biological processes crucial for maintaining homeostasis and responding to different stimuli. Consequently, several challenges have emerged during the efforts made to translate basic research data into clinical applications. In this review, we present both physiological and pathological roles of cysteine cathepsins and discuss the clinical potential of cysteine cathepsin-targeting strategies for disease management and diagnosis.
Collapse
Affiliation(s)
- Monika Biasizzo
- Jozef Stefan Institute, Department of Biochemistry and Molecular and Structural Biology, Jamova 39, SI-1000, Ljubljana, Slovenia; International Postgraduate School Jozef Stefan, Jamova 39, SI-1000, Ljubljana, Slovenia
| | - Urban Javoršek
- Jozef Stefan Institute, Department of Biochemistry and Molecular and Structural Biology, Jamova 39, SI-1000, Ljubljana, Slovenia; International Postgraduate School Jozef Stefan, Jamova 39, SI-1000, Ljubljana, Slovenia
| | - Eva Vidak
- Jozef Stefan Institute, Department of Biochemistry and Molecular and Structural Biology, Jamova 39, SI-1000, Ljubljana, Slovenia; International Postgraduate School Jozef Stefan, Jamova 39, SI-1000, Ljubljana, Slovenia
| | - Miki Zarić
- Jozef Stefan Institute, Department of Biochemistry and Molecular and Structural Biology, Jamova 39, SI-1000, Ljubljana, Slovenia; International Postgraduate School Jozef Stefan, Jamova 39, SI-1000, Ljubljana, Slovenia
| | - Boris Turk
- Jozef Stefan Institute, Department of Biochemistry and Molecular and Structural Biology, Jamova 39, SI-1000, Ljubljana, Slovenia; Faculty of Chemistry and Chemical Technology, University of Ljubljana, Vecna pot 113, SI-1000, Ljubljana, Slovenia.
| |
Collapse
|
2
|
Fan W, Zhang W, Allen S, Alshehri S, Muilenburg KM, Zheng C, Garrison JC. Examination of Charge Modifications of an Endolysosomal Trapping Inhibitor in an Antagonistic NTSR1-Targeted Construct for Colon Cancer. Bioconjug Chem 2022; 33:1363-1376. [PMID: 35793523 PMCID: PMC9941984 DOI: 10.1021/acs.bioconjchem.2c00214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Many low-molecular weight targeted radiotherapeutics (TRTs) are capable of rapidly achieving exceptional tumor to non-target ratios shortly after administration. However, the low tumor residence time of many TRTs limits therapeutic dose delivery and has become the Achilles heel to their clinical translation. To combat the tumor efflux of these otherwise promising agents, we have previously presented a strategy of equipping low-molecular weight TRTs with irreversible cysteine cathepsin inhibitors (e.g., E-64 analogues). These inhibitors are capable of forming irreversible adducts with cysteine proteases within the endolysosomal compartments of cells. Using these endolysosomal trapping agents (ETs), the receptor-targeted constructs are able to increase tumor retention and, thus, deliverable therapeutic doses. In this study, we examine this approach in the development of agents targeting the neurotensin receptor subtype 1 (NTSR1), a receptor overexpressed in numerous cancers. Using an antagonistic NTSR1-targeting vector, we explore the impact of charge modification of the ETs on the in vitro and in vivo biological performance of the constructs using HT-29 colon cancer models. Four ETs (based on the epoxysuccinyl peptide E-64) with various charge states were synthesized and incorporated into the structures of the NTSR1-targeted antagonist. These four 177Lu-labeled, ET-enhanced, NTSR1-targeted agents (177Lu-NA-ET1-4), along with the structurally analogous 177Lu-3BP-227, currently in clinical trials, underwent a battery of in vitro assays using HT-29 xenograft colon cancer cells to examine their NTSR1 binding, internalization and efflux, inhibition, and adduct formation properties. The biodistribution profile of these constructs was studied in an HT-29 mouse model. Charge modification of the terminal carboxylic acid and arginine of the ETs had deleterious effects on inhibition kinetics and in vitro adduct formation. Contrastingly, deletion of the arginine resulted in a modest increase in inhibition kinetics. Incorporation of ETs into the NTSR1-targeted agents was well-tolerated with minimal impact on the in vivo NTSR1 targeting but resulted in increased renal uptake. This study demonstrates that the ETs can be successfully incorporated into antagonistic NTSR1-targeted constructs without compromising their adduct formation capabilities. Based on these results, further exploration of the endolysosomal trapping approach is warranted in NTSR1- and other receptor-targeted antagonistic constructs.
Collapse
Affiliation(s)
- Wei Fan
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE,Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE
| | - Wenting Zhang
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE,Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE
| | - Sadie Allen
- Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE
| | - Sameer Alshehri
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE,Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE
| | - Kathryn M Muilenburg
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE,Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE
| | - Cheng Zheng
- Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE
| | - Jered C. Garrison
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE,Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE,Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE,Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE,Corresponding Author Jered C. Garrison, Tel: +01 4025593453.
| |
Collapse
|
3
|
Fan W, Zhang W, Alshehri S, Garrison JC. Examination of the impact molecular charge has on NTSR1-targeted agents incorporated with cysteine protease inhibitors. Eur J Med Chem 2022; 234:114241. [PMID: 35306289 PMCID: PMC9007894 DOI: 10.1016/j.ejmech.2022.114241] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2021] [Revised: 02/21/2022] [Accepted: 02/25/2022] [Indexed: 02/05/2023]
Abstract
Our laboratory has previously reported a strategy of employing cysteine cathepsin (CC) inhibitors as adduct forming, trapping agents to extend the tumor residence time of neurotensin receptor subtype 1 (NTSR1)-targeted radiopharmaceuticals. As a follow-up, we herein report a small library of CC trapping agent (CCTA)-incorporated, NTSR1-targeted conjugates with structural modifications that reduce the number of charged functional groups for both the CCTA and the peptide targeting sequence. These modifications were pursued to reduce the renal uptake and increase the translational potential of the CCTA-incorporated, NTSR1-targeted agents as radiotherapeutics. The biological performance of these constructs was examined using a battery of in vitro and in vivo studies employing the NTSR1-positive HT-29 human colon cancer cell line as our model. In vitro studies confirmed the ability of these constructs to target the NTSR1 and efficiently form intracellular adducts with cysteine proteases. Biodistribution studies using an HT-29 xenograft mouse model revealed that truncation (removal of Lys6-Pro7) of the NTSR1-targeted peptide (177Lu-NE2a) had the greatest (3.7-fold) effect at lowering renal recognition/uptake relative to our previously reported construct. Other charge-reducing modifications to the CCTA resulted in unexpected increases in renal uptake. All of the constructs demonstrated similar levels of in vivo NTSR1-positive tumor targeting with the highest tumor residualization resulting from the construct containing the zwitterionic CCTA (177Lu-NE2a). In vivo adduct formation of the conjugates was confirmed using autoradiographic SDS-PAGE analysis.
Collapse
Affiliation(s)
- Wei Fan
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, NE 68198, United States,Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, NE 68198, United States
| | - Wenting Zhang
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, NE 68198, United States,Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, NE 68198, United States
| | - Sameer Alshehri
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, NE 68198, United States,Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, NE 68198, United States
| | - Jered C. Garrison
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, NE 68198, United States,Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, NE 68198, United States,Department of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, 985870 Nebraska Medical Center, Omaha, NE 68198, United States,Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, 985950 Nebraska Medical Center, Omaha, NE 68105, United States,Corresponding author: Tel: +01 4025593453,
| |
Collapse
|
4
|
Guan Q, Zhou L, Lv F, Li W, Li Y, Dong Y. A Glycosylated Covalent Organic Framework Equipped with BODIPY and CaCO
3
for Synergistic Tumor Therapy. Angew Chem Int Ed Engl 2020. [DOI: 10.1002/ange.202008055] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Qun Guan
- College of Chemistry, Chemical Engineering and Materials Science Collaborative Innovation Center of Functionalized Probes for, Chemical Imaging in Universities of Shandong Key Laboratory of Molecular and Nano Probes Ministry of Education Shandong Normal University Jinan 250014 P. R. China
| | - Le‐Le Zhou
- College of Chemistry, Chemical Engineering and Materials Science Collaborative Innovation Center of Functionalized Probes for, Chemical Imaging in Universities of Shandong Key Laboratory of Molecular and Nano Probes Ministry of Education Shandong Normal University Jinan 250014 P. R. China
| | - Fan‐Hong Lv
- College of Chemistry, Chemical Engineering and Materials Science Collaborative Innovation Center of Functionalized Probes for, Chemical Imaging in Universities of Shandong Key Laboratory of Molecular and Nano Probes Ministry of Education Shandong Normal University Jinan 250014 P. R. China
| | - Wen‐Yan Li
- College of Chemistry, Chemical Engineering and Materials Science Collaborative Innovation Center of Functionalized Probes for, Chemical Imaging in Universities of Shandong Key Laboratory of Molecular and Nano Probes Ministry of Education Shandong Normal University Jinan 250014 P. R. China
| | - Yan‐An Li
- College of Chemistry, Chemical Engineering and Materials Science Collaborative Innovation Center of Functionalized Probes for, Chemical Imaging in Universities of Shandong Key Laboratory of Molecular and Nano Probes Ministry of Education Shandong Normal University Jinan 250014 P. R. China
| | - Yu‐Bin Dong
- College of Chemistry, Chemical Engineering and Materials Science Collaborative Innovation Center of Functionalized Probes for, Chemical Imaging in Universities of Shandong Key Laboratory of Molecular and Nano Probes Ministry of Education Shandong Normal University Jinan 250014 P. R. China
| |
Collapse
|
5
|
Guan Q, Zhou L, Lv F, Li W, Li Y, Dong Y. A Glycosylated Covalent Organic Framework Equipped with BODIPY and CaCO
3
for Synergistic Tumor Therapy. Angew Chem Int Ed Engl 2020; 59:18042-18047. [DOI: 10.1002/anie.202008055] [Citation(s) in RCA: 69] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2020] [Indexed: 12/22/2022]
Affiliation(s)
- Qun Guan
- College of Chemistry, Chemical Engineering and Materials Science Collaborative Innovation Center of Functionalized Probes for, Chemical Imaging in Universities of Shandong Key Laboratory of Molecular and Nano Probes Ministry of Education Shandong Normal University Jinan 250014 P. R. China
| | - Le‐Le Zhou
- College of Chemistry, Chemical Engineering and Materials Science Collaborative Innovation Center of Functionalized Probes for, Chemical Imaging in Universities of Shandong Key Laboratory of Molecular and Nano Probes Ministry of Education Shandong Normal University Jinan 250014 P. R. China
| | - Fan‐Hong Lv
- College of Chemistry, Chemical Engineering and Materials Science Collaborative Innovation Center of Functionalized Probes for, Chemical Imaging in Universities of Shandong Key Laboratory of Molecular and Nano Probes Ministry of Education Shandong Normal University Jinan 250014 P. R. China
| | - Wen‐Yan Li
- College of Chemistry, Chemical Engineering and Materials Science Collaborative Innovation Center of Functionalized Probes for, Chemical Imaging in Universities of Shandong Key Laboratory of Molecular and Nano Probes Ministry of Education Shandong Normal University Jinan 250014 P. R. China
| | - Yan‐An Li
- College of Chemistry, Chemical Engineering and Materials Science Collaborative Innovation Center of Functionalized Probes for, Chemical Imaging in Universities of Shandong Key Laboratory of Molecular and Nano Probes Ministry of Education Shandong Normal University Jinan 250014 P. R. China
| | - Yu‐Bin Dong
- College of Chemistry, Chemical Engineering and Materials Science Collaborative Innovation Center of Functionalized Probes for, Chemical Imaging in Universities of Shandong Key Laboratory of Molecular and Nano Probes Ministry of Education Shandong Normal University Jinan 250014 P. R. China
| |
Collapse
|
6
|
Tabish TA, Pranjol MZI, Whatmore JL, Zhang S. Status and Future Directions of Anti-metastatic Cancer Nanomedicines for the Inhibition of Cathepsin L. FRONTIERS IN NANOTECHNOLOGY 2020. [DOI: 10.3389/fnano.2020.00001] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
|
7
|
Zhang W, Fan W, Ottemann BM, Alshehri S, Garrison JC. Development of Improved Tumor-Residualizing, GRPR-Targeted Agents: Preclinical Comparison of an Endolysosomal Trapping Approach in Agonistic and Antagonistic Constructs. J Nucl Med 2019; 61:443-450. [PMID: 31601697 DOI: 10.2967/jnumed.119.231282] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2019] [Accepted: 09/09/2019] [Indexed: 02/07/2023] Open
Abstract
Receptor-targeted radiopharmaceuticals based on low-molecular-weight carriers offer many clinically advantageous attributes relative to macromolecules but have generally been hampered by their rapid clearance from tumors, thus diminishing tumor-to-nontarget tissue ratios. Herein, we present a strategy using irreversible inhibitors (E-64 derivative) of cysteine cathepsins (CCs) as trapping agents to increase the tumor retention of receptor-targeted agents. Methods: We incorporated these CC-trapping agents into agonistic and antagonistic pharmacophores targeting the gastrin-releasing peptide receptor (GRPR). The synthesized radioconjugates with either an incorporated CC inhibitor or a matching control were examined using in vitro and in vivo models of the GRPR-positive, PC-3 human prostate cancer cell line. Results: From the in vitro studies, multiple techniques confirmed that the CC-trapping, GRPR-targeted constructs were able to increase cellular retention by forming intracellular macromolecule adducts. In PC-3 tumor-bearing xenograft mice, the CC-trapping, GRPR-targeted agonistic and antagonistic constructs led to an approximately 2-fold increase in tumor retention with a corresponding improvement in most tumor-to-nontarget tissue ratios over 72 h. Conclusion: CC endolysosomal trapping provides a pathway to increase the efficacy and clinical potential of low-molecular-weight, receptor-targeted agents.
Collapse
Affiliation(s)
- Wenting Zhang
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska.,Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, Nebraska
| | - Wei Fan
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska.,Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, Nebraska
| | - Brendan M Ottemann
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska
| | - Sameer Alshehri
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska.,Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, Nebraska
| | - Jered C Garrison
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska .,Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, Nebraska.,Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska; and.,Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska
| |
Collapse
|
8
|
Fan W, Zhang W, Alshehri S, Neeley TR, Garrison JC. Enhanced tumor retention of NTSR1-targeted agents by employing a hydrophilic cysteine cathepsin inhibitor. Eur J Med Chem 2019; 177:386-400. [PMID: 31158752 DOI: 10.1016/j.ejmech.2019.05.068] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Revised: 05/23/2019] [Accepted: 05/24/2019] [Indexed: 01/09/2023]
Abstract
We explored the approach of using an analog of E-64, a well-known and hydrophilic cysteine cathepsin (CC) inhibitor, as a potent cysteine cathepsin-trapping agent (CCTA) to improve the tumor retention of low-molecular-weight, receptor-targeted radiopharmaceuticals. The synthesized hydrophilic CCTA-incorporated, NTSR1-targeted agents demonstrated a substantial increase in cellular retention upon uptake into the NTRS1-positive HT-29 human colon cancer cell line. Similarly, biodistribution studies using HT-29 xenograft mice revealed a significant and substantial increase in tumor retention for the CCTA-incorporated, NTSR1-targeted agent. The intracellular trapping mechanism of the CCTA-incorporated agents by macromolecular adduct formation was confirmed using multiple in vitro and in vivo techniques. Furthermore, utilization of the more hydrophilic CCTA greatly increased the hydrophilicity of the resulting NTSR1-targeted constructs leading to substantial decreases in most non-target tissues in contrast to our previously reported dipeptidyl acyloxymethyl ketone (AOMK) constructs. This work further confirms that the CCTA trapping approach can make significant improvements in the clinical potential of NTSR1-and other receptor-targeted radiopharmaceuticals.
Collapse
Affiliation(s)
- Wei Fan
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, NE, 68198, United States; Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, NE, 68198, United States
| | - Wenting Zhang
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, NE, 68198, United States; Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, NE, 68198, United States
| | - Sameer Alshehri
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, NE, 68198, United States; Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, NE, 68198, United States
| | - Trey R Neeley
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, NE, 68198, United States; Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, NE, 68198, United States
| | - Jered C Garrison
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, NE, 68198, United States; Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, NE, 68198, United States; Department of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, 985870 Nebraska Medical Center, Omaha, NE, 68198, United States; Eppley Cancer Center, University of Nebraska Medical Center, 985950 Nebraska Medical Center, Omaha, NE, 68198, United States.
| |
Collapse
|